The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example
2:30 pm - Tuesday 13th October 2026
- Understanding the MoA of T-DXd and potential for T-DXd to move from advanced to early oncology settings
- Identifying rationale-driven research to identify combination partners complimentary to T-DXd mechanism
- Reviewing clinical data of T-DXd from late-line HER2+ metastatic breast and gastric cancer to first-line approval combination therapy in HER2+ metastatic breast cancer and earlier-line metastatic gastric cancer settings